Roger Dansey, Seagen interim CEO

Seagen se­cures a speedy FDA re­view on Tukysa as Mer­ck buy­out talks re­port­ed­ly stall

Af­ter ru­mors of stalled buy­out talks be­tween Mer­ck and Seagen, per­haps a new Tukysa in­di­ca­tion could reignite in­ter­est.

The FDA has grant­ed Tukysa a pri­or­i­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.